Application Period
Noon, Friday, February 17, 2025
–
Noon, Friday, April 25, 2025
(JST/GMT+9)
Noon, Friday, May 9, 2025
(JST/GMT+9)
Application Eligibility
Foreign presenters and Co-speakers do not have to be members of the Japanese Association for Thoracic Surgery (JATS).
For those who are interested in becoming JATS members, please contact the Japanese Association for Thoracic Surgery:
1F Teral Koraku Building, 2-3-27 Koraku, Bunkyo-ku, Tokyo 112-0004, JAPAN
Phone: +81-3-3812-4253 Fax: +81-3-3816-4560
URL: http://www.jpats.org/ E-mail: jats-adm@umin.ac.jp
Notes
- Presentations must be of original material and being presented for the first time.
- Once presentations are approved by the Program Committee, Copyright of the presentations will be assumed by the Japanese Association for Thoracic Surgery.
Submissions
1) Recommended Browsers
To use the online abstract submission system, please use the latest version of Firefox, Google Chrome, Microsoft Edge or Safari.
Internet Explorer (IE) or any other browsers are non-compliant browsers for the online abstract submission system.
2) Abstract Submission Number and Password
During the course of entering your information, you will be required to set your own password.
Upon completion of the abstract submission process, you will be given your abstract submission number. Your abstract submission number and password are very important, so please keep them safe and confidential.
We, the Program Secretariat, will use the abstract submission number when contacting you.
Please note we will not respond to inquiries regarding security issues. Your abstract submission number and password may be used to login and modify your abstract and information up until the submission deadline (noon, April 25, 2025, JST/GMT+9).
3) Abstract Specifications
Language |
English |
Abstract Title |
Limited to 200 characters |
Abstract Body |
Limited to 2,000 characters |
Figures and Tables |
A single GIF or JPEG file no larger than 300KB (Portrait or landscape accepted; size will be reduced to approximately 6*4 cm). |
4) Confirmation of Submission
After submitting your abstract, you will receive a confirmation e-mail. You may use the submission link to view and modify your abstract at any time up until the abstract submission deadline.
If you do not receive confirmation by e-mail, please contact the Program Secretariat:jats2025-abs@congre.co.jp
5) Notification of Acceptance
The Program committee will carefully review all submitted abstracts, consider the reviews, and then make a final decision on which papers to select.
The first author will receive a notification of acceptance via email by the end of July.
The paper selection results will also be listed on the congress website.
Following the notification of acceptance, the first author must register for the 78th Annual Meeting, and abstracts can only be presented upon receipt of the registration fee.
Call for Primary Sessions
Cardiovascular Surgery
1)Panel Discussion
「Ross procedure: Outcomes and future directions」
- Outline
- The Ross procedure is gaining attention for younger patients due to benefits like improved survival and no need for anticoagulation. This panel will discuss the latest insights, addressing its indications, challenges like homograft availability, and future directions to optimize its use and outcomes.
2)Symposium
「Reconsoderation of valve sparing root replacement」
- Outline
- Valve-sparing aortic root replacement has become so widespread that it can be considered a standard procedure, In this session, we will discuss the indications for the procedure, what is necessary for further improvement of the results, and points to keep in mind when performing reoperation.
3)Symposium
「Facts about preemptive TEVAR」
- Outline
- Preemptive TEVAR is recommended for high-risk cases that are expected to expand in the future, but what is the current situation in Japan as an actual practice? Based on the mid-term results, we will discuss detailed indications, timing of intervention, and treatment methods beyond the guidelines.
Thoracic Surgery
1)Symposium
「Surgeon Training in the era of technical innovation」
- Outline
- As minimally invasive surgeries such as robotic and uniport approaches have become more widespread and technological innovations such as surgical instruments and devices have continued to advance, the digital transformation (DX), such as preoperative image simulation systems and VR technology, will be expected in surgeon training. Furthermore, from the perspective of medical safety, on-the-job training for young surgeons is limited, and the importance of off-the-job training is increasing. In this session, we would like to discuss the educational policies and training methods of each country and reconsider the education of young surgeons who will lead the next generation.
2)Panel Discussion
「The current position of RATS: Well, what's the robot like?」
- Outline
- Since RATS was covered by health insurance in 2018, the number of cases has been increasing year by year, and recently, it has been performed at about 5,000 cases per year. In addition to the conventional Davinci (X/Xi), new models have been introduced since 2023, bringing fresh air to the field of thoracic surgery. In this session, we will clarify the features of each model and present their respective range of applications and techniques, aiming to promote the safe and useful dissemination of RATS.
Call for Oral/Mini Oral Sessions
T. Cross-disciplinary
1 |
T-1 |
Cross-disciplinary/Combined cardiothoracic surgery (heart/aorta+α) |
2 |
T-2 |
Cross-disciplinary/Combined cardiothoracic surgery (lung+α) |
3 |
T-3 |
Cross-disciplinary/Combined cardiothoracic surgery (esophagus+α) |
H. Heart
4 |
H-1 |
Acyanotic congenital heart disease |
5 |
H-2 |
Aortic arch anomaly/coarctation of aorta |
6 |
H-3 |
Hypoplastic left heart syndrome: HLHS |
7 |
H-4 |
Transposition of great arteries |
8 |
H-5 |
Miscellaneous cyanotic diseases |
9 |
H-6 |
Long-term issues/complications |
10 |
H-7 |
Adult congenital heart disease |
11 |
H-8 |
Congenital heart disease others |
12 |
H-9 |
Valvular disease-aortic |
13 |
H-10 |
Valvular disease-mitral |
14 |
H-11 |
Valvular disease-tricuspid |
15 |
H-12 |
Valvular disease-pulmonary |
16 |
H-13 |
Valvular disease-combined |
17 |
H-14 |
Valvular disease-MICS/Robotics |
18 |
H-15 |
Valvular disease-TAVI/MitraClip |
19 |
H-16 |
Valvular disease-infective endocarditis |
20 |
H-17 |
Valvular disease-others |
21 |
H-18 |
Ischemic heart disease-CABG |
22 |
H-19 |
Ischemic heart disease-minimally invasive CABG |
23 |
H-20 |
Ischemic heart disease-complications of myocardial infarction |
24 |
H-21 |
Ischemic heart disease-others |
25 |
H-22 |
Aorta-type A dissection |
26 |
H-23 |
Aorta-type B dissection |
27 |
H-24 |
Aorta-complications of aortic dissection |
28 |
H-25 |
Aorta-aortic root |
29 |
H-26 |
Aorta-ascending/arch |
30 |
H-27 |
Aorta-descending |
31 |
H-28 |
Aorta-thoracoabdominal |
32 |
H-29 |
Aorta-esophageal/bronchial fistula |
33 |
H-30 |
Aorta-infected aneurysm/graft infection |
34 |
H-31 |
Aorta-others |
35 |
H-32 |
Combined surgery (valve, coronary, aorta, etc.) |
36 |
H-33 |
Arrhythmia, pacemaker |
37 |
H-34 |
Maze surgery |
38 |
H-35 |
Closure/resection of LAA |
39 |
H-36 |
Cardiac tumor |
40 |
H-37 |
Cardiomyopathy/myocarditis |
41 |
H-38 |
Heart/heart-lung transplantation |
42 |
H-39 |
Myocardial protection and metabolism |
43 |
H-40 |
Extracorporeal circulation |
44 |
H-41 |
Assisted circulation/ventricular assisted system |
45 |
H-42 |
Perioperative management and complications |
46 |
H-43 |
Examination and diagnosis |
47 |
H-44 |
Experiment |
48 |
H-45 |
New surgical techniques |
49 |
H-46 |
Development and innovation |
50 |
H-47 |
Regenerative medicine and tissue engineering |
51 |
H-48 |
Others |
L. Lung
52 |
L-1 |
Lung cancer |
53 |
L-2 |
Pulmonary metastasis |
54 |
L-3 |
Pulmonary neuroendocrine tumor |
55 |
L-4 |
Mediastinum (thymic disease) |
56 |
L-5 |
Mediastinum (non-thymic disease) |
57 |
L-6 |
Pleura, chest wall, and thorax |
58 |
L-7 |
Trachea and bronchus |
59 |
L-8 |
Pneumothorax and emphysematous/bullous lung disease |
60 |
L-9 |
Inflammatory lung diseases |
61 |
L-10 |
Benign lung tumor |
62 |
L-11 |
Pediatric lung disease |
63 |
L-12 |
Minimally invasive surgery (Video-assisted and Robot-assisted thoracic surgery) |
64 |
L-13 |
Salvage surgery, relapse therapy, oligometastases |
65 |
L-14 |
Lung transplantation and assisted circulation |
66 |
L-15 |
New surgical techniques・device |
67 |
L-16 |
Perioperative management and complications and high-risk patients |
68 |
L-17 |
Examination and diagnosis |
69 |
L-18 |
Gene and molecular biology |
70 |
L-19 |
Regenerative medicine |
71 |
L-20 |
Others(education・work share・team medicine・others) |
E. Esophagus
72 |
E-1 |
Esophageal malignancies |
73 |
E-2 |
Esophageal benign diseases |
74 |
E-3 |
Barrett's esophagus and adenocarcinoma |
75 |
E-4 |
Esophagectomy and lymphadenectomy |
76 |
E-5 |
Esophageal reconstruction |
77 |
E-6 |
Minimally invasive and robot-assisted surgery |
78 |
E-7 |
Multidisciplinary treatment |
79 |
E-8 |
Salvage surgery and conversion surgery |
80 |
E-9 |
Treatment for recurrent esophageal cancer |
81 |
E-10 |
Perioperative management and complications |
82 |
E-11 |
Surgical training |
83 |
E-12 |
Aortoesophageal fistula |
84 |
E-13 |
Surgical anatomy |
85 |
E-14 |
Genetics and molecular biology |
86 |
E-15 |
Pathology and experimental research |
87 |
E-16 |
Palliative treatment |
88 |
E-17 |
Esophageal cancer in elderly |
89 |
E-18 |
Multiple primary malignant tumors |
90 |
E-19 |
Others |
7) Presentation format
Information about presentation format and methodology requirements will be released in due course. These requirements are subject to change. Applicants are advised to check the website for the latest information.
Abstract Submission
Ciphertext-based(recommended)
Inquiries
Secretariat of the 78th Annual Scientific Meeting of the Japanese Association for Thoracic Surgery
c/o Congrès Inc.
E-mail: jats2025-abs@congre.co.jp